Background and Aims. In diabetic patients, chronic kidney disease (CKD) requires special attention due to the multitude of factors that determine glycemic variability. We aimed to assess glycemic variability in patients with CKD and type 2 diabetes mellitus (T2DM) using a continuous glucose monitoring system (CGMS) and identify the predictive value of inter-day and intra-day glycemic variability indices for metabolic imbalance. Material and method. We included 20 diabetic patients (10 CKD patients/10 patients without CKD) and 10 healthy volunteers. Anthropometric parameters, glycated hemoglobin (HbA1c), and glycemic variability indices on CGMS readings were registered. Results. CKD diabetic patients presented significantly higher inter-day and intra-day glycemic variability compared to the diabetic patients without CKD. HbA1c was not significantly different between diabetic subjects with/without CKD. ROC curves indicated that just some CGMS parameters had higher predictive value for metabolic imbalance (HbA1c≥6.5%) but only the percentage of time with glucose values>180 mg/dl (p=0.024) was an independent predictor for HbA1c≥6.5%. Conclusions. Subjects with CKD and T2DM had poor glycemic control and significantly higher glycemic variability comparative to those without CKD, and especially to healthy volunteers. Assessment of glycemic variability indices is more accurate than HbA1c for the quantification of glycemic control in CKD diabetic patients
1. IDF Diabetes Atlas Group. Update of mortality attributable to diabetes for the IDF Diabetes Atlas: estimates for the year 2011. Diabetes Res Clin Pract 100: 277-279, 2013.
2. Hossain MP, Goyder EC, Rigby JE, El NahasM. CKD and poverty: A growing global challenge. Am JKidney Dis 53: 166-174, 2009.
3. Hudson M, Inrig J, Barboza J. Secondary Prevention: Clinical approaches to managing the higher - risk patient with heart disease. Accessed at http://www.medscape.org/viewarticle/768623 in June 2013
4. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 60: 850-886, 2012.
5. Mircescu G, Garneata L. Dialysis renal replacement therapy in Romania. Renal Romanian Register. srnefro.ro/media/RRR.Raport.2011.pdf. 2011
6. Siegelaar SE, Holleman F, HoekstraJB, DeVries JH. Glucose variability; does it matter? Endocr Rev 31: 171-182, 2010.
7. Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295: 1681-1687, 2006.
8. Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J DiabetesSci Technol 2: 1094-1100, 2008.
9. Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care 31: S150- S154, 2008.
10. Nelson RG, Tuttle KR. The new KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and CKD. Blood Purif 25: 112-114, 2007.
12. Johnson EL. Glycemic variability in type 2 diabetes mellitus: oxidative stress and macrovascular complications. Adv Exp Med Biol 771: 139-154, 2012.
13. Twomey PJ, Wierzbicki AS, Reynolds TM. Issues to consider when attempting to achieve the American Diabetes Association clinical quality requirement for haemoglobin A1c. Curr Med Res Opin 9: 719-723, 2003.
14. Rodbard D. Glycemic variability: measurement and utility in clinical medicine and research--one viewpoint. Diabetes Technol Ther 13: 1077-1080, 2011.
15. www.pediatria.umed.pl/team/glyculator. Accessed in June 2013
16. Czerwoniuk D, Fendler W, Walenciak L,Mlynarski W. GlyCulator: a glycemic variability calculation tool for continuous glucose monitoring data. JDiabetes Sci Technol 5: 447-451, 2011.
17. Wójcicki JM. Mathematical descriptions of the glucose control in diabetes therapy. Analysis of the Schlichtkrull "M"-value. Horm Metab Res 27: 1-5, 1995.
18. Fendler W, Tucholski K, Walenciak L, Jarosz-Chobot P, Mlynarski W. Fractal dimension analysis of continuous glucose monitoring data in screening for hypoglycemia-prone patients with type 1 diabetes - preliminary report. 2nd International Conference on Advanced Technologies and Treatments for Diabetes, 2009. (Abstract)
19. Higuchi T. Approach to an irregular time series on the basis of the fractal theory. Physica D 31: 277-283, 1988.
20. Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia 8: 342-348, 1972 .
21. Vos FE, Schollum JB, Coulter CV, ManningPJ, Duffull SB, Walker RJ. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. Nephrology(Carlton) 17: 182 -188, 2012.
22. Kazempour-Ardebili S, Lecamwasam VL,Dassanyake T et al. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care 32: 1137-1142, 2009.
23. Riveline JP, Teynie J, Belmouaz S et al. Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant 24: 2866-2871, 2009.
24. Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron 61: 377-382, 1992.